Welcome, Guest
Username: Password: Remember me
Adult Stem Cell News and Developments other than Cytori
  • Page:
  • 1

TOPIC: Osteoarthritis Trial from SVF in U.S.

Osteoarthritis Trial from SVF in U.S. 17 Mar 2016 14:20 #6665

  • Wall Street Titan
  • Wall Street Titan's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 887
  • Thank you received: 148
Competition on the way. More importantly these guys are using 100,000,000 cells. I've said before, it could very well be that 40,000,000 cells is not enough. This is a Phase II from this study I previously discussed that showed healthy cartilage growth at 100MM cells and a dose related response. The trial design for Cytori OA trial may be flawed, IMHO: could be the reason we saw no dose related response.



South Korean biotechnology firm Nature Cell on Monday said it has begun Phase II clinical trials on its stem cell-based osteoarthritis treatment in the U.S., drawing a step closer to commercializing the new drug overseas.

Osteoarthritis, sometimes called degenerative joint disease, is the most common chronic condition of the joints, occurring most often in the knees, hips, lower back and neck, according to the U.S.-based Arthritis Foundation.


Dubbed “Joint Stem,” Nature Cell’s new therapy uses about 10 grams of fat tissue extracted from a given patient’s glenoid cavity to incubate some 100 million mesenchymal stem cells, which are later compressed into a 3 cubic-centimeters injection.

About three weeks after their fat tissues are extracted, patients can begin receiving a “Joint Stem” injection once a week. They are able to see their cartilage restored in about six months through regular injections, instead of through surgery, the firm said.

The Biostar Research Lab, jointly operated by Nature Cell and R Bio, is currently incubating stem cells based on fat tissue samples from two U.S. patients. The injections will begin to be administered on April 4 at a hospital in Los Angeles.

The firm plans to recruit a total of 45 local patients at two additional hospitals in the U.S. and complete all the injections by September.

Stem cells — progenitor cells able to develop into various types of tissue — are perceived as the key to advances in regenerative medicine which help the body heal itself. They are known to be particularly effective in regenerating damaged cartilage.

There are around 54 million degenerative arthritis patients in the U.S., of which some 760,000 patients undergo surgery that costs an average of 40 million won ($33,706), according to the U.S. Center of Disease Control and Prevention.

Please Log in or Create an account to join the conversation.

Osteoarthritis Trial from SVF in U.S. 17 Mar 2016 14:43 #6666

  • myownhedgefund
  • myownhedgefund's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2822
  • Thank you received: 202
WST
Everyone wants a piece of the osteoarthritis market because it will be huge.
The company I posted about the other day is involved in it.
On the number of cells....perhaps potency is a factor and Cytori can get by with fewer.
On the other side of the coin, it may all end up as another Cytori failure added to the long list.
Nearly a year (48 wks) is a long time to wait for stat sig separation...your guys claim cartilage regrowth in 26 weeks.

:KO:

Please Log in or Create an account to join the conversation.

Osteoarthritis Trial from SVF in U.S. 17 Mar 2016 16:41 #6667

  • Wall Street Titan
  • Wall Street Titan's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 887
  • Thank you received: 148
"your guys claim cartilage regrowth in 26 weeks."

Its more than a claim. They did it with the 100,000,000 dose: http://onlinelibrary.wiley.com/enhanced/doi/10.1002/stem.1634#stem1634-bib-0016 Now they are doing the study in the U.S.

Please Log in or Create an account to join the conversation.

  • Page:
  • 1
Time to create page: 0.108 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites